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The introduction of vaccinations has represented one of the most important breakthroughs
for global health, resulting in significant reductions in mortality and morbidity in the general
population with positive impacts also on economic growth (Parretta et al., 2011; Pellegrino
et al., 2015; World Health Organization1; I vaccini e le vaccinazioni2). Still, coverage for highly
recommended vaccines is far from optimal, especially in children: 1 in 10 children worldwide did
not receive any vaccinations in 2016 with an average of almost 3 million deaths each year due to
vaccine-preventable infections (Greenwood, 2014; World Health Organization3).
This is not restricted to underdeveloped countries. It has been observed also in developed
countries, such as the US, where a decrease in vaccination coverage was observed in children.
This was mainly induced by a substantial increase in vaccine hesitancy among parents who chose
to excuse their children from school-entry vaccination requirements for non-medical reasons
(Delamater et al., 2018). A decrease in vaccination coverage was observed in US also for adult
patients, as highlighted by a recent study that analyzed data from the 2015 National Health
Interview Survey; it confirmed that, except for a moderate gain for some vaccines, coverage was
low (Williams et al., 2017). Likewise, in some European countries vaccination coverage is not
adequate (Esposito, 2014). Vaccination coverage is a growing concern in Italy: on December 2017,
the Italian Ministry of Health reported 4.885 measles cases and 4 deaths from January 1st 2017.
Among those cases, 88% were unvaccinated, while 6% were vaccinated with only one dose4.
This situation did not escape the attention of the World Health Organization, which underlined
how Italy is becoming a problem in the European health scenario, considering that 43% of all
measles cases recorded in Europe have occurred in our country. Paradoxically it is the success
of vaccination that contributes to the present worsening scenario. The success of vaccination
strategies and the almost complete disappearance of some diseases has reduced the perception
of the danger of contagion and facilitated the spread of movements opposed to vaccinations, for
ethical or religious reasons, or for fear of vaccines-induced adverse events. The negative trend
of vaccination in Italy dates back to 2013; this decline involved mandatory vaccinations (anti-
diphtheria, anti-polio, anti-tetanic, anti-hepatitis B), and some of those recommended, except
for pneumococcal and meningococcal coverage which have instead increased (Pezzotti et al.,
2018).
1World Health Organization. Immunization coverage. Available online at: http://www.who.int/mediacentre/factsheets/fs378/
en/ (last access 15-02-2018).
2I vaccini e le vaccinazioni. Available online at: https://www.fimp.pro/images/vaccini.pdf (last access 15-02-2018).
3World Health Organization. 1 in 10 infants worldwide did not receive any vaccinations in 2016. Available at: http://www.
who.int/mediacentre/news/releases/2017/infants-worldwide-vaccinations/en/ (last access 15-02-2018).
4Measles in Italy: weekly bullettin. Available online at: http://www.epicentro.iss.it/problemi/morbillo/bollettino/
Measles_WeeklyReport_N35eng.pdf (last access 16-02-2018).
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The good news is that Italy has eventually initiated to reverse this
course thanks to a new law, dating from last year, the so-called
Lorenzin decree, which became law in July 2017 (Law 119/2017 -
GU Serie Generale n.182 del 05-08-2017), a move that anticipated
the new French law highlighted in a recent Nature Editorial
(2018, 2018). The law now renders 10 vaccinations compulsory
and free of charge for all pediatric patients aged 0–16. The Italian
Ministry of Health have also drawn up a vaccination calendar,
which was included in the National Vaccination Prevention Plan
(Piano Nazionale Prevenzione Vaccinale) 2017–2019, approved
in the State-Regions Conference5,6. In particular, for children
from 0 to 6 years, vaccinations which are totally subsidized by
the Italian National Health Service now include anti-diphtheria,
anti-polio, anti-tetanus, anti-viral hepatitis B, anti-pertussis, anti-
H. influenzae B, anti-measles, anti-mumps, and anti-rubella
(all mandatory for those born in 2001 or later), and anti-
chicken pox (mandatory for those born in 2017 or later).
Additionally, further vaccinations are strongly recommended
in specific patients’ age group, such as the anti-meningococcal
B and anti-rotavirus for those born in 2017 or later, anti-
pneumococcal and anti-meningococcal C for those born in 2012
or later. For teenagers, the booster dose of anti-diphtheria, anti-
polio, anti-tetanic, and anti-pertussis are also mandatory for
patients born in 2001 or later, anti-HPV for girls and boys (2
times during the 12th year of life), and the tetravalent anti-
meningococcal for adolescents. Finally, anti-pneumococcal, anti-
zoster and anti-flu for adult over 64 years are recommended5,6.
Considering its features, the main aims of National Vaccination
Prevention Plan are to keep polio-free status, reach the
measles- and rubella-free status, ensure the free active offer
of vaccinations for frail and vulnerable groups of populations,
complete the computerization of the immunological registry,
improve the surveillance of preventable diseases by vaccination,
and foster research and scientific information on vaccines.
The new Law brings novelties also for school registration and
attendance. In fact, on March 10th 2018, the deadline for
the presentation of compulsory vaccinations’ documentation
expired. Consequently, approximately 20 children who haven’t
had all their immunizations were sent home; they will be
readmitted as soon as they have been vaccinated.
This new Law is aimed to achieve the highest coverage
in immunization, avoiding the return of vaccine-preventable
diseases, and to overcome barriers in immunization, including
those related to parents and healthcare providers. Recently, the
Italian National Institute of Public Health (Istituto Superiore di
Sanità) coordinated a survey among parents of children aged 16–
36 months, finding that, among 3.130 questionnaires evaluated,
vaccine-hesitant parents were 16%, while 39% had doubts about
vaccinating their children. According to authors’ findings, among
the European countries, Italy has the highest levels of skepticism
5Conferenza Permanente per I Rapporti tra lo Stato le Regioni e le Province
Autonome di Trento e Bolzano. Available at: http://www.trovanorme.salute.gov.
it/norme/dettaglioAtto?id=58185 (last access 15-02-2018).
6Aspetti operativi per la piena e uniforme implementazione del nuovo PNPV
2017-2019 e del relativo Calendario Vaccinale. Available online at: http://
www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2017&codLeg=
58583&parte=1%20&serie=null (last access 15-02-2018).
related to effectiveness and safety of vaccines (Giambi et al.,
2018). Several factors may have contributed to a decline of
confidence in vaccines: the fear of adverse events induced
by toxic substances (mercury, aluminum or other dangerous
chemical agents); the belief that children’s immune system is too
immature to respond to vaccines and that the natural exposure to
vaccine-preventable diseases provides more enduring immunity;
the spread of fake news, especially those related to measles,
mumps and rubella (MMR) vaccine-induced autism, despite
no evidence existing of a causal association between the MMR
vaccine and autism spectrum disorders (Honda et al., 2005;
Godlee et al., 2011; Smith, 2017). These results demonstrated
that old beliefs, especially those related to the safety profile of
vaccines, are still rooted in Italy and that it is neither simple
nor immediate to counteract the so-called vaccine hesitancy
(MacDonald and SAGE Working Group on Vaccine Hesitancy,
2015).
Ten months have passed since the approval of the Law
119/2017, but can we say now that this strategy does work?
According to what recently reported by Signorelli et al. (2018),
it does; available preliminary data (from June to October
2017) referred to five Italian Regions revealed that, compared
with 2016, vaccine coverage rises of 1% for the hexavalent
vaccine (against diphtheria, tetanus, pertussis, poliomyelitis,
H. influenzae B, and hepatitis B) and of 2.9% for the MMR
vaccine. Moreover, on March 2018, the Italian National Institute
of Public Health declared that the country has reached its
goal for hexavalent vaccine coverage (more than 95%)7. This
increase is expected to bring huge consequences especially
for frail and vulnerable population, such as newborn babies,
pregnant women, patients without a fully working immune
system, including those on chemotherapy treatment and patients
affected by HIV. In addition to this, it would be beneficial
an increase also in the coverage for flu vaccination that has
been falling in European countries in recent years. It would
significantly improve clinical conditions of high risk adults
and children, elderly and hospitalized patients as well as those
affected by chronic cardiovascular, metabolic and respiratory
diseases.
The Italian Law, while effective in terms of efficacy in
the absence of safety issues, still attracted criticism not
only from the anti-vaccine groups but also from politicians
especially because of its imperative modalities. We agree
with the concept reported in the editorial mentioned (2018),
“Laws are not the only way to boost immunization”. In our
opinion, the continuous monitoring of vaccination coverage,
along with the guarantee of free vaccinations to the target
population, do represent effective strategies in order to
achieve global immunization goals and effectively contrast
vaccine concerns not consistent with scientific knowledge.
Moreover, an effective risk communication, mainly based on
transparency, dialogue, and scientific exchange of information
on vaccines between interested parties, may help to solve
7Vaccine goal achieved, 95% coverage – ISS. Available online at: http://www.ansa.
it/english/news/2018/03/12/vaccine-goal-achieved-95-coverage-iss-3_f73aff94-
cde5-4430-b1f9-fe89d5248b44.html (last access 12-04-2018).
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a worldwide emergency leading to increase in vaccination
coverage.
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